Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief

Oliver William Massey; Cenk Suphioglu

doi:10.3390/ijms231911166

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief

Oliver William Massey
, Cenk Suphioglu

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.

Original language	English
Article number	11166
Number of pages	13
Journal	International Journal of Molecular Sciences
Volume	23
Issue number	19
DOIs	https://doi.org/10.3390/ijms231911166
Publication status	Published - 1 Oct 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

asthma
Benralizumab
eosinophilic inflammation
immunotherapy
Interleukin-5
Mepolizumab
Reslizumab

Access to Document

10.3390/ijms231911166Licence: CC BY

Final published versionFinal published version, 2.64 MBLicence: CC BY

Cite this

@article{98e3b9cb65fc4aa68846cdfd5e0ebea3,

title = "Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief",

abstract = "Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.",

keywords = "asthma, Benralizumab, eosinophilic inflammation, immunotherapy, Interleukin-5, Mepolizumab, Reslizumab",

author = "Massey, \{Oliver William\} and Cenk Suphioglu",

year = "2022",

month = oct,

day = "1",

doi = "10.3390/ijms231911166",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI",

number = "19",

}

TY - JOUR

T1 - Taking a Breather

T2 - Advances in Interleukin 5 Inhibition for Asthma Relief

AU - Massey, Oliver William

AU - Suphioglu, Cenk

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.

AB - Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.

KW - asthma

KW - Benralizumab

KW - eosinophilic inflammation

KW - immunotherapy

KW - Interleukin-5

KW - Mepolizumab

KW - Reslizumab

UR - https://www.scopus.com/pages/publications/85139879967

U2 - 10.3390/ijms231911166

DO - 10.3390/ijms231911166

M3 - Review article

C2 - 36232470

AN - SCOPUS:85139879967

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 19

M1 - 11166

ER -

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this